The Humanized Platelet Glycoprotein VI Fab Inhibitor EMA601 Protects from Arterial Thrombosis and Ischaemic Stroke in Mice

Overview

Journal Eur Heart J

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2024 Aug 16

PMID 39150906

Authors

Stefano Navarro

Ivan Talucci

Vanessa Gob

Stefanie Hartmann

Sarah Beck

Valerie Orth

Guido Stoll

Hans M Maric

David Stegner

Bernhard Nieswandt

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Glycoprotein VI (GPVI) is a platelet collagen/fibrin(ogen) receptor and an emerging pharmacological target for the treatment of thrombotic and thrombo-inflammatory diseases, notably ischaemic stroke. A first anti-human GPVI (hGPVI) antibody Fab-fragment (ACT017/glenzocimab, KD: 4.1 nM) recently passed a clinical phase 1b/2a study in patients with acute ischaemic stroke and was found to be well tolerated, safe, and potentially beneficial. In this study, a novel humanized anti-GPVI antibody Fab-fragment (EMA601; KD: 0.195 nM) was developed that inhibits hGPVI function with very high potency in vitro and in vivo.

Methods: Fab-fragments of the mouse anti-hGPVI IgG Emf6.1 were tested for functional GPVI inhibition in human platelets and in hGPVI expressing (hGP6tg/tg) mouse platelets. The in vivo effect of Emf6.1Fab was assessed in a tail bleeding assay, an arterial thrombosis model and the transient middle cerebral artery occlusion (tMCAO) model of ischaemic stroke. Using complementary-determining region grafting, a humanized version of Emf6.1Fab (EMA601) was generated. Emf6.1Fab/EMA601 interaction with hGPVI was mapped in array format and kinetics and quantified by bio-layer interferometry.

Results: Emf6.1Fab (KD: 0.427 nM) blocked GPVI function in human and hGP6tg/tg mouse platelets in multiple assays in vitro at concentrations ≥5 µg/mL. Emf6.1Fab (4 mg/kg)-treated hGP6tg/tg mice showed potent hGPVI inhibition ex vivo and were profoundly protected from arterial thrombosis as well as from cerebral infarct growth after tMCAO, whereas tail-bleeding times remained unaffected. Emf6.1Fab binds to a so far undescribed membrane proximal epitope in GPVI. The humanized variant EMA601 displayed further increased affinity for hGPVI (KD: 0.195 nM) and fully inhibited the receptor at 0.5 µg/mL, corresponding to a >50-fold potency compared with ACT017.

Conclusions: EMA601 is a conceptually novel and promising anti-platelet agent to efficiently prevent or treat arterial thrombosis and thrombo-inflammatory pathologies in humans at risk.

Citing Articles

A New Perspective on Mechanisms of Neurodegeneration in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: the Early and Critical Role of Platelets in Neuro/Axonal Loss.

Orian J J Neuroimmune Pharmacol. 2025; 20(1):14.

PMID: 39904925 PMC: 11794395. DOI: 10.1007/s11481-025-10182-w.

Specificities of Myocardial Infarction and Heart Failure in Women.

Dekleva M, Djordjevic A, Zivkovic S, Suzic Lazic J J Clin Med. 2024; 13(23).

PMID: 39685777 PMC: 11642064. DOI: 10.3390/jcm13237319.

Ischemia/reperfusion injury in acute human and experimental stroke: focus on thrombo-inflammatory mechanisms and treatments.

Stoll G, Nieswandt B, Schuhmann M Neurol Res Pract. 2024; 6(1):57.

PMID: 39582054 PMC: 11587771. DOI: 10.1186/s42466-024-00355-y.

One immune cell to bind them all: platelet contribution to neurodegenerative disease.

Rodriguez Moore G, Melo-Escobar I, Stegner D, Bracko O Mol Neurodegener. 2024; 19(1):65.

PMID: 39334369 PMC: 11438031. DOI: 10.1186/s13024-024-00754-4.

Thromboinflammation is associated with clinical outcome after ST-elevation myocardial infarction.

Benkhoff M, Alde K, Ehreiser V, Dahlmanns J, Metzen D, Haurand J Blood Adv. 2024; 8(21):5581-5589.

PMID: 39226457 PMC: 11541696. DOI: 10.1182/bloodadvances.2024014273.

References

Rex N, McDonough R, Ospel J, Kashani N, Sehgal A, Fladt J . CT Perfusion Does Not Modify the Effect of Reperfusion in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment in the ESCAPE-NA1 Trial. AJNR Am J Neuroradiol. 2023; 44(9):1045-1049. PMC: 10494951. DOI: 10.3174/ajnr.A7954. View

Horii K, Kahn M, Herr A . Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood. 2006; 108(3):936-42. DOI: 10.1182/blood-2006-01-010215. View

Arthur J, Dunkley S, Andrews R . Platelet glycoprotein VI-related clinical defects. Br J Haematol. 2007; 139(3):363-72. DOI: 10.1111/j.1365-2141.2007.06799.x. View

Feitsma L, Brondijk H, Jarvis G, Hagemans D, Bihan D, Jerah N . Structural insights into collagen binding by platelet receptor glycoprotein VI. Blood. 2022; 139(20):3087-3098. DOI: 10.1182/blood.2021013614. View

Schulz C, Penz S, Hoffmann C, Langer H, Gillitzer A, Schneider S . Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol. 2008; 103(4):356-67. DOI: 10.1007/s00395-008-0722-3. View

Devi S, Kuligowski M, Kwan R, Westein E, Jackson S, Kitching A . Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway. Am J Pathol. 2010; 177(3):1131-42. PMC: 2928948. DOI: 10.2353/ajpath.2010.091143. View

Rayes J, Watson S, Nieswandt B . Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019; 129(1):12-23. PMC: 6307936. DOI: 10.1172/JCI122955. View

Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H . Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J. 2006; 27(18):2165-9. DOI: 10.1093/eurheartj/ehl192. View

Pachel C, Mathes D, Arias-Loza A, Heitzmann W, Nordbeck P, Deppermann C . Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-Reperfusion Injury. Arterioscler Thromb Vasc Biol. 2016; 36(4):629-35. DOI: 10.1161/ATVBAHA.115.305873. View

10.

Taylor L, Vasudevan S, Jones C, Gibbins J, Churchill G, Duncan Campbell R . Discovery of novel GPVI receptor antagonists by structure-based repurposing. PLoS One. 2014; 9(6):e101209. PMC: 4074120. DOI: 10.1371/journal.pone.0101209. View

11.

Mangin P, Onselaer M, Receveur N, Le Lay N, Hardy A, Wilson C . Immobilized fibrinogen activates human platelets through glycoprotein VI. Haematologica. 2018; 103(5):898-907. PMC: 5927996. DOI: 10.3324/haematol.2017.182972. View

12.

Andresen H, Zarse K, Grotzinger C, Hollidt J, Ehrentreich-Forster E, Bier F . Development of peptide microarrays for epitope mapping of antibodies against the human TSH receptor. J Immunol Methods. 2006; 315(1-2):11-8. DOI: 10.1016/j.jim.2006.06.012. View

13.

Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave J . Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001; 193(4):459-69. PMC: 2195902. DOI: 10.1084/jem.193.4.459. View

14.

Boylan B, Berndt M, Kahn M, Newman P . Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood. 2006; 108(3):908-14. PMC: 1895852. DOI: 10.1182/blood-2005-07-2937. View

15.

Stoll G, Schuhmann M, Kollikowski A, Pham M . New mechanisms-based therapies in acute ischaemic stroke. Eur Heart J. 2024; 45(14):1190-1192. DOI: 10.1093/eurheartj/ehad865. View

16.

Matus V, Valenzuela G, Saez C, Hidalgo P, Lagos M, Aranda E . An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost. 2013; 11(9):1751-9. DOI: 10.1111/jth.12334. View

17.

Lecut C, Feeney L, Kingsbury G, Hopkins J, Lanza F, Gachet C . Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost. 2003; 1(12):2653-62. DOI: 10.1111/j.1538-7836.2003.00495.x. View

18.

Navarro S, Starke A, Heemskerk J, Kuijpers M, Stegner D, Nieswandt B . Targeting of a Conserved Epitope in Mouse and Human GPVI Differently Affects Receptor Function. Int J Mol Sci. 2022; 23(15). PMC: 9369317. DOI: 10.3390/ijms23158610. View

19.

Mangin P, Tang C, Bourdon C, Loyau S, Freund M, Hechler B . A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharmacol Exp Ther. 2012; 341(1):156-63. DOI: 10.1124/jpet.111.189050. View

20.

Gruner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung S . Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood. 2004; 105(4):1492-9. DOI: 10.1182/blood-2004-06-2391. View